Navigation Links
Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
Date:8/28/2008

us

S. aureus is the most frequent cause of hospital-acquired infections. In addition to bloodstream infections with a mortality rate of up to 35%, infections of bone, heart and other inner organs are leading to serious health complications, death and economic burden. Today, approximately 50% of S. aureus strains isolated in hospitals worldwide are resistant to multiple antibiotics, rendering staphylococcal disease management increasingly difficult and challenging. Hospital-acquired infections are one of the major causes of death and serious illness worldwide, resulting in an annual burden of more than USD 20 billion in the developed world. In the United States alone, about two million patients become infected annually while receiving health care in hospitals.

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, successfully concluded pivotal Phase III clinical trials in 2006 and is currently in the process of market approval in the US, Europe, Australia and Canada. Market approval in the US, Europe and Australia is expected for the second half of 2008.

The company's broad development pipeline includes a Travelers' Diarrhea vaccine (patch) in Phase II (start of Phase III expected in 2009), a Pseudomonas vaccine in Phase II, as well as an immunostimulant vaccine patch in pandemic Flu, a partnered S. aureus vaccine in Phas
'/>"/>

SOURCE Intercell AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 ... and marketer of innovative medical devices for the treatment of ... prevailed in a final opposition appeal hearing in the European ... - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent has ... has been upheld as a valid patent in amended form. ...
(Date:7/1/2015)... July 1, 2015 Dynatronics Corporation (the ... marketer of rehabilitation and physical therapy products, announced ... placement financing led by affiliates of Prettybrook Partners ... focused on the healthcare industry. The financing provides ... and pursue potential strategic acquisitions.  ...
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  MEI Pharma, ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at the inaugural Cantor Fitzgerald Healthcare ... time from Le Parker Meridien in ... can be accessed at www.meipharma.com . A replay will ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2
... NEW YORK and WASHINGTON, May 14 Revolution ... up to offer patients and,physicians the largest personalized ... United States. Individuals can quickly assess their,eligibility for ... confidential,and efficient way through an online search engine ...
... with Scripps Florida and Scripps Research in La ... ... FRANCISCO, Calif., and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard ... and The Scripps Research,Institute, a non-profit biomedical research organization, today announced,that ...
Cached Medicine Technology:Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:7/1/2015)... , ... July 01, 2015 , ... For decades, researchers ... wound, histones, remain constant in the brain, never changing after development in the womb. ... histones are steadily replaced in brain cells throughout life – a process which helps ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... technology and services, today announced that its fifth annual Smile for a Lifetime ... $80,000 for the non-profit organization. In addition to supporting S4L in its mission ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of ... the DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and Families (CCF) ... The grant will allow CCF to improve quality of care and save costs for ... to respond to many changes in New York’s Medicaid system. Experts agree that children ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... Sellamuthu, has ordered distribution of AIDS/HIV awareness calendar to ... tea stalls, hair cutting saloons and Indian Made Foreign ... large number of public gather. The idea of AIDS ... Control Society (TANSACS), according to the officials the calendar ...
... smokers or those who have been smoking in the past have ... tomography (CT scan) to detect // lung cancer if any, ... effective treatment and thereby improve the prognosis. ,The ... family history of the dreadful disease. For those of you ...
... to effective weight loss apart from diet and exercise. ... several myths abound // . Let’s throw some light ... and dispel famous myths to reveal underlying truths!, ,Body ... happens when calorie intake exceeds calories expended. The extra ...
... doctors of Indian origin live in a state of penury in ... of them even have decent // lodgings. This is the ... to serve in the country in 2001, which had resulted in ... ,Most of them are faced with discrimination and unemployment ...
... made news recently due to its wide spreading nature across the ... its // spread across the country. It ... reduced and area, which has been infected with the avian flu, ... that previously there were21 provinces affected with bird flu but now ...
... now proven by research. Apparently genuine laughter is the ... Review of Biology//. ,The study, which explains how ... that there are two types of laughter – genuine and ... second, is strategic and, at times, downright cruel, also nicknamed ...
Cached Medicine News:Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2Health News:The weight loss reality check – Do Fad diets and short-cut methods actually work 2Health News:Genuine Laughter Is The Best Medicine! 2
... technology - Until now, if you wanted ... some of your patients while continuing to ... of patients, you had to keep a ... that has changed with Lifecard 12 - ...
... This direct fluorescent assays ... immunofluorescence technique to provide clear, ... 15 minutes. Chlamydia antigens ... antibody to the C. trachomatis ...
Inquire...
... Brachytherapy loaders allow for efficient, easy ... Connectors to your customized plans at ... Bard loaders is the flexibility to ... flexibility of the patented SourceLink™ Connector ...
Medicine Products: